Skip to main content
. 2020 Jul 22;8(2):e000342. doi: 10.1136/jitc-2019-000342

Figure 2.

Figure 2

Investigator-assessed progression-free survival in patients treated with AS/OBI-821 or placebo. Kaplan–Meier estimates; modified intent-to-treat population.